After treating more than 50,000 patients in Norway in just six months, Nolla is expanding to 40+ U.S. states
Nolla Health, a Norway-born healthtech startup, is entering the U.S. market with a $4.5 million seed round led by General Catalyst.
After treating more than 50,000 patients in Europe and becoming one of Norway’s top five medical apps, the company is setting up its U.S. headquarters in New York City and launching its Acne Care app across 40 states.
Nolla is positioning itself as an alternative to the current patchwork of digital health solutions, aiming to deliver end-to-end care rather than relying on legacy systems or overburdened telehealth providers. Its subscription model costs $59 per month and includes daily AI-powered skin scans, clinician-reviewed treatment plans, and topical medications shipped directly to patients.
“Having someone who knows your medical history, is always available, and truly personalizes your care shouldn’t be a luxury,” said Luis Wenus, the co-founder and CEO of Nolla Health. “With today’s technology, we can finally begin to deliver that experience for everyone.”
In the U.S., the average wait to see a dermatologist is 36 days, and conditions like acne affect up to 50 million people each year, according to data cited by Nola. The startup’s technology is trained on more than one million dermatology cases across 1,600 conditions, and allows patients to receive diagnoses and prescriptions within hours. In Norway, the system also flagged thousands of suspicious lesions for follow-up.
In addition to General Catalyst, the seed round also drew investment from SNO Ventures and Commure founder Diede van Lamoen.
Nolla plans to use the capital to expand its U.S. operations, add clinical and engineering staff, and develop additional apps targeting other conditions. The company’s Acne Care app is now available in more than 40 states, the company’s first step in its broader vision to build AI-powered “personal care companions.”
